ArticleNucleic acids research2026
Enhancing ribosomal translation of backbone-altering nonproteinogenic amino acids via YebC and YeeN.
Article in Nucleic acids research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Development of genetic code reprogramming methodologies has enabled the ribosomal incorporation of diverse backbone-altering nonproteinogenic amino acids (BAAs)-including d-α-amino acids, β-amino acids, and N-methyl-α-amino acids-into nascent peptides. However, their incorporation is far less efficient than that of canonical l-α-amino acids. We previously demonstrated that the ribosomal E-site-binding translation factors, EF-P and ABC-F proteins, can enhance BAA incorporation. These findings motivated us to investigate additional ribosome-binding factors that might further facilitate this process. Here, we focused on two putative A-site-binding factors, YebC and YeeN, to activate A-site BAA-tRNA and facilitate efficient incorporation. When testing 11 BAAs for consecutive incorporation, YebC and YeeN yielded average enhancements of 2.1- and 2.7-fold, respectively, with an increase of up to 6.6-fold in specific cases. Furthermore, combining YebC with EF-P and Uup (a representative ABC-F protein) produced an 8.0-fold increase in the incorporation of two consecutive N-methyl-l-leucine residues, demonstrating a clear synergistic benefit. We also found that YebC and YeeN promote ribosomal synthesis of drug-like macrocyclic peptides enriched with BAAs, such as d-serine, 1-aminocyclobutane-1-carboxylic acid, N-methyl-l-alanine, and β3-homomethionine. These results pave the way for the ribosomal synthesis of diverse macrocyclic peptide libraries and their application in mRNA display-based screening for novel bioactive compounds.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.